Home
Storia in 2 fonti
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.
- ·
statnews.com
Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study
Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.
- ·
cnbc.com
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.